Osteoarthritis (OA) is associated with the degradation of aggrecan by aggrecanases (e.g. ADAMTS-4, ADAMTS-5) ultimately leading, to the reduction of daily physical activity in aged individuals. The cleavage of aggrecan by aggrecanases generates a series of neoepitope exposed fragments (e.,. NITEGE) in both animal models and osteoarthritic patients. These aggrecan fragments can be used for identifying disease associated biomarkers for the purpose of measuring the efficacy of therapeutic agents in vivo. A monoclonal antibody, 681-3 mab was developed which recognizes the C-terminal neoepitope NITEGE following aggrecan cleavage by aggrecanases. The 681-3 mab has a K-D of 4.03 x 10(-10) M as determined by Biacore analysis. A polyclonal antibody, NEP522 which specifically binds to intact aggrecan was also developed. These antibodies were used to develop a highly sensitive assay with lower detection limits of 125 pM which was capable of detecting NITEGE fragments in ADAMTS-4/5 digested human aggrecan and in IL-1 alpha stimulated bovine nasal cartilage disk cultures. The NITEGE 681-3/NEP522 sandwich ELISA has applications for screening compounds for aggrecanase(s) inhibitory activity, selection of appropriate OA models, the evaluation of compound efficacy in vivo, as well as the potential to stratify patients for clinical trial design. (C) 2007 Elsevier B.V. All rights reserved.